A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: presently (14)

Enhanced recovery after anti-reflux surgery - patient information

Description
This factsheet is designed to help increase your understanding of the enhanced recovery programme, and to enable you and your family
Url
/Media/UHS-website-2019/Patientinformation/Surgery/Enhanced-recovery-after-anti-reflux-surgery-3319-PIL.pdf

UHS Inclusion and Belonging Strategy

Description
Our strategy sets out clear actions we will take to make UHS a place where every person feels they belong and
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/uhs-inclusion-and-belonging-strategy.pdf

WDES annual report 2022

Description
Workforce Disability Equality Standard - Annual Report 2022 2 Executive Summary The Workforce Disability Equality Standard (WDES) is a se
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Workforce-Disability-Equality-Standard-Annual-Report-2022.docx

Atezolizumab-Bevacizumab

Description
Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezo
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

UHSNFT Ultrasound Referral guidelines for GPs V6- new neck referral included

Description
UNIVERSITY HOPSITAL SOUTHAMPTON GUIDELINES FOR GP ULTRASOUND REFERRALS IN ADULTS Introduction Ultrasound is often used as a first line inve
Url
/Media/UHS-website-2019/Docs/Services/Radiology/UHSNFT-Ultrasound-Referral-guidelines-for-GPs-V6-new-neck-referral-included.pdf

Endovascular aneurysm repair (EVAR) - patient information

Description
Information about endovascular aneurysm repair (EVAR
Url
/Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Endovascular-aneurysm-repair-EVAR-1657-PIL.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with;
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC af
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Cisplatin-Pembrolizumab-Pemetrexed

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) CISPLATIN-PEMBROLIZUMAB-PEMETREXED Regimen • NSCLC – Cisplatin-Pembrolizumab-Pemetrexed In
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Cisplatin-Pembrolizumab-Pemetrexed.pdf
361 to 370 of 411
Previous … 35 36 37 38 39 … Next